Specialty business set to spur growth for Sun Pharma in next 3 yrs: Experts

Global specialty drug sales for Sun Pharma have grown by 39% YoY in FY22 to $674 million

Specialty drugs are likely to be the key growth drivers for Sun Pharma in the next three years, according to analysts.

Global specialty drug sales for Sun Pharma have grown by 39 per cent year-on-year (YoY) in FY22 to $674 million. In the fourth quarter, the company recorded a 30 per cent growth in specialty revenues to $185 million across all markets.

The growth was led by Ilumya (psoriasis drug), Cequa (dry eye medicine), and Odomzo (cancer drug).

Dilip Shanghvi, managing director (MD), Sun Pharma said that the contribution from the specialty portfolio nearly doubled to 13 per cent in